Antibody therapy for histoplasmosis

Joshua D. Nosanchuk, Rosely M. Zancopé-Oliveira, Andrew J. Hamilton, Allan J. Guimarães

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

The endemic human pathogenicfungusHistoplasmacapsulatum isamajor fungal pathogen with a broad variety of clinical presentations, ranging from mild, focal pulmonary disease to life-threatening systemic infections. Although azoles, such as itraconazole and voriconazole, and amphotericin B have significant activity against H. capsulatum, about 1 in 10 patients hospitalized due to histoplasmosis die. Hence, new approaches for managing disease are being sought. Over the past 10years, studies have demonstrated that monoclonal antibodies (mAbs) can modify the pathogenesis of histoplasmosis. Disease has been shown to be impacted by mAbs targeting either fungal cell surface proteins or host co-stimulatory molecules. This review will detail our current knowledge regarding the impact of antibody therapy on histoplasmosis.

Original languageEnglish (US)
Article numberArticle 21
JournalFrontiers in Microbiology
Volume3
Issue numberFEB
DOIs
StatePublished - 2012

Fingerprint

Histoplasmosis
Antibodies
Monoclonal Antibodies
Azoles
Itraconazole
Amphotericin B
Lung Diseases
Membrane Proteins
Therapeutics
Infection

Keywords

  • Antibody
  • Co-stimulation
  • Heat shock protein 60
  • Histone 2B
  • Histoplasma capsulatum
  • Histoplasmosis
  • M antigen

ASJC Scopus subject areas

  • Microbiology
  • Microbiology (medical)

Cite this

Nosanchuk, J. D., Zancopé-Oliveira, R. M., Hamilton, A. J., & Guimarães, A. J. (2012). Antibody therapy for histoplasmosis. Frontiers in Microbiology, 3(FEB), [Article 21]. https://doi.org/10.3389/fmicb.2012.00021

Antibody therapy for histoplasmosis. / Nosanchuk, Joshua D.; Zancopé-Oliveira, Rosely M.; Hamilton, Andrew J.; Guimarães, Allan J.

In: Frontiers in Microbiology, Vol. 3, No. FEB, Article 21, 2012.

Research output: Contribution to journalArticle

Nosanchuk, JD, Zancopé-Oliveira, RM, Hamilton, AJ & Guimarães, AJ 2012, 'Antibody therapy for histoplasmosis', Frontiers in Microbiology, vol. 3, no. FEB, Article 21. https://doi.org/10.3389/fmicb.2012.00021
Nosanchuk JD, Zancopé-Oliveira RM, Hamilton AJ, Guimarães AJ. Antibody therapy for histoplasmosis. Frontiers in Microbiology. 2012;3(FEB). Article 21. https://doi.org/10.3389/fmicb.2012.00021
Nosanchuk, Joshua D. ; Zancopé-Oliveira, Rosely M. ; Hamilton, Andrew J. ; Guimarães, Allan J. / Antibody therapy for histoplasmosis. In: Frontiers in Microbiology. 2012 ; Vol. 3, No. FEB.
@article{baa43ceb65044be1928125656ae864b7,
title = "Antibody therapy for histoplasmosis",
abstract = "The endemic human pathogenicfungusHistoplasmacapsulatum isamajor fungal pathogen with a broad variety of clinical presentations, ranging from mild, focal pulmonary disease to life-threatening systemic infections. Although azoles, such as itraconazole and voriconazole, and amphotericin B have significant activity against H. capsulatum, about 1 in 10 patients hospitalized due to histoplasmosis die. Hence, new approaches for managing disease are being sought. Over the past 10years, studies have demonstrated that monoclonal antibodies (mAbs) can modify the pathogenesis of histoplasmosis. Disease has been shown to be impacted by mAbs targeting either fungal cell surface proteins or host co-stimulatory molecules. This review will detail our current knowledge regarding the impact of antibody therapy on histoplasmosis.",
keywords = "Antibody, Co-stimulation, Heat shock protein 60, Histone 2B, Histoplasma capsulatum, Histoplasmosis, M antigen",
author = "Nosanchuk, {Joshua D.} and Zancop{\'e}-Oliveira, {Rosely M.} and Hamilton, {Andrew J.} and Guimar{\~a}es, {Allan J.}",
year = "2012",
doi = "10.3389/fmicb.2012.00021",
language = "English (US)",
volume = "3",
journal = "Frontiers in Microbiology",
issn = "1664-302X",
publisher = "Frontiers Media S. A.",
number = "FEB",

}

TY - JOUR

T1 - Antibody therapy for histoplasmosis

AU - Nosanchuk, Joshua D.

AU - Zancopé-Oliveira, Rosely M.

AU - Hamilton, Andrew J.

AU - Guimarães, Allan J.

PY - 2012

Y1 - 2012

N2 - The endemic human pathogenicfungusHistoplasmacapsulatum isamajor fungal pathogen with a broad variety of clinical presentations, ranging from mild, focal pulmonary disease to life-threatening systemic infections. Although azoles, such as itraconazole and voriconazole, and amphotericin B have significant activity against H. capsulatum, about 1 in 10 patients hospitalized due to histoplasmosis die. Hence, new approaches for managing disease are being sought. Over the past 10years, studies have demonstrated that monoclonal antibodies (mAbs) can modify the pathogenesis of histoplasmosis. Disease has been shown to be impacted by mAbs targeting either fungal cell surface proteins or host co-stimulatory molecules. This review will detail our current knowledge regarding the impact of antibody therapy on histoplasmosis.

AB - The endemic human pathogenicfungusHistoplasmacapsulatum isamajor fungal pathogen with a broad variety of clinical presentations, ranging from mild, focal pulmonary disease to life-threatening systemic infections. Although azoles, such as itraconazole and voriconazole, and amphotericin B have significant activity against H. capsulatum, about 1 in 10 patients hospitalized due to histoplasmosis die. Hence, new approaches for managing disease are being sought. Over the past 10years, studies have demonstrated that monoclonal antibodies (mAbs) can modify the pathogenesis of histoplasmosis. Disease has been shown to be impacted by mAbs targeting either fungal cell surface proteins or host co-stimulatory molecules. This review will detail our current knowledge regarding the impact of antibody therapy on histoplasmosis.

KW - Antibody

KW - Co-stimulation

KW - Heat shock protein 60

KW - Histone 2B

KW - Histoplasma capsulatum

KW - Histoplasmosis

KW - M antigen

UR - http://www.scopus.com/inward/record.url?scp=84864451340&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864451340&partnerID=8YFLogxK

U2 - 10.3389/fmicb.2012.00021

DO - 10.3389/fmicb.2012.00021

M3 - Article

C2 - 22347215

AN - SCOPUS:84864451340

VL - 3

JO - Frontiers in Microbiology

JF - Frontiers in Microbiology

SN - 1664-302X

IS - FEB

M1 - Article 21

ER -